322 related articles for article (PubMed ID: 38489062)
41. Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation.
Norman G; Faria R; Paton F; Llewellyn A; Fox D; Palmer S; Clifton I; Paton J; Woolacott N; McKenna C
Health Technol Assess; 2013 Nov; 17(52):1-342. PubMed ID: 24267198
[TBL] [Abstract][Full Text] [Related]
42. Efficacy and Safety of Biologics for Oral Corticosteroid-Dependent Asthma: A Systematic Review and Network Meta-Analysis.
Phinyo P; Krikeerati T; Vichara-Anont I; Thongngarm T
J Allergy Clin Immunol Pract; 2024 Feb; 12(2):409-420. PubMed ID: 37972921
[TBL] [Abstract][Full Text] [Related]
43. Remdesivir in the COVID-19 Pandemic: An Analysis of Spontaneous Reports in VigiBase During 2020.
Rocca E; Gauffin O; Savage R; Vidlin SH; Grundmark B
Drug Saf; 2021 Sep; 44(9):987-998. PubMed ID: 34374967
[TBL] [Abstract][Full Text] [Related]
44. Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics.
Liu MC; Chipps B; Munoz X; Devouassoux G; Bergna M; Smith SG; Price RG; Galkin DV; Azmi J; Mouneimne D; Albers FC; Chapman KR
Respir Res; 2021 May; 22(1):144. PubMed ID: 33971856
[TBL] [Abstract][Full Text] [Related]
45. Biological treatments in childhood asthma.
Nieto-García A; Nieto-Cid M; Mazón-Ramos Á
Curr Opin Allergy Clin Immunol; 2024 Jun; 24(3):114-121. PubMed ID: 38567842
[TBL] [Abstract][Full Text] [Related]
46. [Treatment of refractory asthma with antibodies].
Lommatzsch M
Dtsch Med Wochenschr; 2016 Jun; 141(11):790-3. PubMed ID: 27254629
[TBL] [Abstract][Full Text] [Related]
47. Safety of biological therapy in elderly patients with severe asthma.
Mir-Ihara P; Narváez-Fernández E; Domínguez-Ortega J; Entrala A; Barranco P; Luna-Porta JA; Romero D; Villamañán E; Losantos-García I; Quirce S
J Asthma; 2022 Nov; 59(11):2218-2222. PubMed ID: 34889165
[TBL] [Abstract][Full Text] [Related]
48. Characteristics of new adult users of mepolizumab with asthma in the USA.
Wu AC; McMahon PM; Welch E; McMahill-Walraven CN; Jamal-Allial A; Gallagher M; Zhang T; Draper C; Kline AM; Koerner L; Brown JS; Van Dyke MK
BMJ Open Respir Res; 2021 Nov; 8(1):. PubMed ID: 34732517
[TBL] [Abstract][Full Text] [Related]
49. Improvement in Olfaction in Patients With CRSwNP and Severe Asthma Taking Anti-IgE and Anti-IL-5 Biologics: A Real-Life Study.
Barroso B; Valverde-Monge M; Alobid I; Olaguibel JM; Rial MJ; Quirce S; Arismendi E; Barranco P; Betancor D; Bobolea I; Cárdaba B; Cruz Carmona MJ; Curto E; Domínguez-Ortega J; González-Barcala FJ; Martínez-Rivera C; Mahíllo-Fernández I; Muñoz X; Picado C; Plaza V; Rodrigo Muñoz JM; Soto-Retes L; Valero A; Del Pozo V; Mullol J; Sastre J
J Investig Allergol Clin Immunol; 2023 Feb; 33(1):37-44. PubMed ID: 35416154
[TBL] [Abstract][Full Text] [Related]
50. The clinical profile of benralizumab in the management of severe eosinophilic asthma.
Menzella F; Lusuardi M; Galeone C; Facciolongo N; Zucchi L
Ther Adv Respir Dis; 2016 Dec; 10(6):534-548. PubMed ID: 27612492
[TBL] [Abstract][Full Text] [Related]
51. Comparative Effectiveness of Mepolizumab, Benralizumab, and Dupilumab among Patients with Difficult-to-Control Asthma: A Multicenter Retrospective Propensity-matched Analysis.
Kearney CM; Sangani R; Shankar D; O'Connor GT; Law AC; Walkey AJ; Bosch NA
Ann Am Thorac Soc; 2024 Jun; 21(6):866-874. PubMed ID: 38241013
[No Abstract] [Full Text] [Related]
52. Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience.
Emma R; Morjaria JB; Fuochi V; Polosa R; Caruso M
Ther Adv Respir Dis; 2018; 12():1753466618808490. PubMed ID: 30354852
[TBL] [Abstract][Full Text] [Related]
53. Biologics and Bronchial Thermoplasty for severe refractory asthma treatment: From eligibility criteria to real practice. A cross-sectional study.
Menzella F; Galeone C; Ruggiero P; Bagnasco D; Catellani C; Facciolongo N
Pulm Pharmacol Ther; 2020 Feb; 60():101874. PubMed ID: 31857207
[TBL] [Abstract][Full Text] [Related]
54. Comparative Efficacy of Anti IL-4, IL-5 and IL-13 Drugs for Treatment of Eosinophilic Asthma: A Network Meta-analysis.
Iftikhar IH; Schimmel M; Bender W; Swenson C; Amrol D
Lung; 2018 Oct; 196(5):517-530. PubMed ID: 30167841
[TBL] [Abstract][Full Text] [Related]
55. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma.
Agache I; Rocha C; Beltran J; Song Y; Posso M; Solà I; Alonso-Coello P; Akdis C; Akdis M; Canonica GW; Casale T; Chivato T; Corren J; Del Giacco S; Eiwegger T; Firinu D; Gern JE; Hamelmann E; Hanania N; Mäkelä M; Martín IH; Nair P; O'Mahony L; Papadopoulos NG; Papi A; Park HS; Pérez de Llano L; Quirce S; Sastre J; Shamji M; Schwarze J; Canelo-Aybar C; Palomares O; Jutel M
Allergy; 2020 May; 75(5):1043-1057. PubMed ID: 32064642
[TBL] [Abstract][Full Text] [Related]
56. [Biologics for the treatment of severe asthma: Current status report 2023].
Paçacı Çetin G; Kepil Özdemir S; Can Bostan Ö; Öztop N; Çelebi Sözener Z; Karakaya G; Gelincik Akkor A; Yılmaz İ; Mungan D; Bavbek S
Tuberk Toraks; 2023 Jun; 71(2):176-187. PubMed ID: 37345400
[TBL] [Abstract][Full Text] [Related]
57. Cost-effectiveness analysis of dupilumab versus omalizumab, mepolizumab, and benralizumab added to the standard of care in adults with severe asthma in Colombia.
Ali A; García E; Torres-Duque CA; Rey D; Botero L; Saenz S; Avila MP; Mazo E; Londoño S
Expert Rev Pharmacoecon Outcomes Res; 2024 Mar; 24(3):361-374. PubMed ID: 37994432
[TBL] [Abstract][Full Text] [Related]
58. Comparison of Monoclonal Antibodies for Treatment of Uncontrolled Eosinophilic Asthma.
Koski RR; Grzegorczyk KM
J Pharm Pract; 2020 Aug; 33(4):513-522. PubMed ID: 31046541
[TBL] [Abstract][Full Text] [Related]
59. Upper and lower airway inflammation in severe asthmatics: a guide for a precision biologic treatment.
Latorre M; Bacci E; Seccia V; Bartoli ML; Cardini C; Cianchetti S; Cristofani L; Di Franco A; Miccoli M; Puxeddu I; Celi A; Paggiaro P
Ther Adv Respir Dis; 2020; 14():1753466620965151. PubMed ID: 33263506
[TBL] [Abstract][Full Text] [Related]
60. Nonsteroidal Anti-inflammatory Drug (NSAID) Tolerance After Biological Therapy in Patients With NSAID-Exacerbated Respiratory Disease: A Randomized Comparative Trial.
Sánchez J; García E; Lopez JF; Calle A; Buendia JA
J Allergy Clin Immunol Pract; 2023 Jul; 11(7):2172-2179. PubMed ID: 37146885
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]